Journal
Gynecologic oncology
Publication Date
3-1-2020
Volume
156
Issue
3
First Page
575
Last Page
582
Document Type
Open Access Publication
DOI
10.1016/j.ygyno.2019.12.039
Rights and Permissions
Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, Bidzinski M, Cebotaru CL, Dutcus CE, Ren M, Kadowaki T, Funahashi Y, Penson RT. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020 Mar;156(3):575-582. doi.org/10.1016/j.ygyno.2019.12.039. © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/)
Recommended Citation
Vergote, Ignace; Powell, Matthew A; Teneriello, Michael G; Miller, David S; Garcia, Agustin A; Mikheeva, Olga N; Bidzinski, Mariusz; Cebotaru, Cristina Ligia; Dutcus, Corina E; Ren, Min; Kadowaki, Tadashi; Funahashi, Yasuhiro; and Penson, Richard T, "Second-line lenvatinib in patients with recurrent endometrial cancer." Gynecologic oncology. 156, 3. 575 - 582. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/11857
Table S1 Summary of exposure to lenvatinib.
mmc2.docx (50 kB)
Table S2 Treatment-related TEAEs leading to study-drug discontinuation.
mmc3.docx (53 kB)
Table S3 Association between baseline levels of circulating cytokines and angiogenic factors with clinical outcomes by independent assessment.
mmc4.docx (50 kB)
Table S4 ORR by baseline Ang-2 level, based on independent radiologic review.
mmc5.docx (220 kB)
Fig. S1 Patient disposition.
mmc6.docx (173 kB)
Fig. S2 Circulating cytokine and angiogenic factor analysis.
